Page 61 - Read Online

Staging Project: proposals regarding the relevance of TNM in the molecules on cell proliferation. Am J Physiol Endocrinol Metab
pathologic staging of small cell lung cancer in the forthcoming 2005;289:E1044-50.
(seventh) edition of the TNM classification for lung cancer. J 28. Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M,
Thorac Oncol 2009;4:1049-59. Neuhaus C, Jürgensen R, Stein K, Schäfer H, Bruns C, Dennler
9. Faggiano A, Sabourin JC, Ducreux M, Lumbroso J, Duvillard P, HJ. Somatostatin analogue octreotide and inhibition of tumour
Leboulleux S, Dromain C, Colao A, Schlumberger M, Baudin E. growth in metastatic endocrine gastroenteropancreatic tumours. Gut
Pulmonary and extrapulmonary poorly differentiated large cell 1996;38:430-8.
neuroendocrine carcinomas: diagnostic and prognostic features. 29. De Sà SV, Corrêa-Giannella ML, Machado MC, de Souza JJ,
Cancer 2007;110:265-74. Pereira MA, Patzina RA, Siqueira SA, Machado MC, Giannella-
10. Travis WD. Advances in neuroendocrine lung tumors. Ann Oncol Neto D. Somatostatin receptors subtype 5 (SSTR5) mRNA
2010; 21 Suppl 7:vii65-71. expression is related to histopatological features of cell proliferation
11. Rekhtmann N. Neuroendocrine tumors of the lung: an update. Arch in insulinomas. Endocr Relat Cancer 2006;13:69-78.
Pathol Lab Med 2010;134:1628-38. 30. Schmid HA, Lambertini C, van Vugt HH, Barzaghi-Rinaudo P,
12. Bertino EM, Confer PD, Colonna JE, Ross P, Otterson Schafer J, Hillenbrand R, Sailer AW, Kaufmann M, Nuciforo P.
GA. Pulmonary neuroendocrine/carcinoid tumors. Cancer Monoclonal antibodies against the human somatostatin receptor
2009;115:4434-41. subtypes 1-5: development and immunohistochemical application
13. Valente M, Catena L, Milione M, Pusceddu S, Formisano B, Bajetta in neuroendocrine tumours. Neuroendocrinology 2012;95:232-47.
E. Common diagnostic challenges in the histopathologic diagnosis 31. Reubi JC, Laissue J, Krenning E, Lamberts SW. Somatostatin
of neuroendocrine lung tumors: a case report. Case Rep Oncol receptors in human cancer: incidence, characteristics, functional
2010;3:202-7. correlates and clinical implications. J Steroid Biochem Mol Biol
14. Oberg KE. The management of neuroendocrine tumours: current 1992;4:27-35.
and future medical therapy options. Clin Oncol (R Coll Radiol) 32. Reubi JC. Peptide receptors as molecular targets for cancer
2012;24:282-93. diagnosis and therapy. Endocr Rev 2003;24:389-427.
15. Reubi JC. Peptide receptors as molecular targets for cancer 33. Reubi JC, Waser B. Concomitant expression of several peptide
diagnosis and therapy. Endocr Rev 2003;24:389-427. receptors in neuroendocrine tumours: molecular basis for in vivo
16. Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: multireceptor tumour targeting. Eur J Nucl Med Mol Imaging
somatostatin analogues in the treatment of gastroenteropancreatic 2003;30:781-93.
neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 34. Reubi JC. Somatostatin and other Peptide receptors as tools for
2010;31:169-88. tumour diagnosis and treatment. Neuroendocrinology 2004;80
17. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. Suppl 1:51-6.
SOM230: a novel somatostatin peptidomimetic with broad 35. Reubi JC, Kappeler A, Wase B, Laissue J, Hipkin RW, Schonbrunn
somatotropin release inhibiting factor (SRIF) receptor binding and A. Immunoistochemical localisation of somatostatin receptros
a unique antisecretory profile. Eur J Endocrinol 2002;146:707-16. SST2A in human tumours. Am J Pathol 1998;153:233-45.
18. Patel YC. Somatostatin and its receptor family. Front 36. Papotti M, Bongiovanni M, Volante M, Allìa E, Landolfi S, Helboe
Neuroendocrinol 1999;20:157-98. L, Schindler M, Cole SL, Bussolati G. Expression of somatostatin
19. Møller LN, Stidsen CE, Hartmann B, Holst JJ. Somatostatin receptros type 1-5 in 81 cases og gastrointestinal and pancreatic
receptors. Biochim Biophys Acta 2003;1616:1-84. endocrine tumours. A correlative immunohistochemical and
20. Ruszniewski P, Ducreux M, Charyvialle JA, Blumberg J, Cloarec D, reverse-transcriptase polymerase chain reaction analysis. Virchovs
Michel H, Raymond JM, Dupas JL, Gouerou H, Jian R, Genestin Arch 2002;440:461-75.
E, Bernades P, Rougier P. Treatment of the carcinoid syndrome with 37. Volante M, Rosas R, Allìa E, Granata R, Baragli A, Muccioli G,
the long acting somatostatin analogue lanreotide: a prospective Papotti M. Somatostatin, cortistatin and their receptors in tumours.
study in 39 patients. Gut 1996;39:279-83. Mol Cell Endocrinol 2008;286:219-29.
21. Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S. Cloning 38. Lahlou H, Guillermet J, Hortala M, Vernejoul F, Pyronnet S,
and functional characterization of a family of human and mouse Bousquet C, Susini C. Molecular signalling of somatostatin
somatostatin receptors expressed in brain, gastrointestinal tract, and receptors. Ann N Y Acad Sci 2004;1014:121-31.
kidney. Proc Natl Acad Sci U S A 1992;89:251-5. 39. Reisine T, Bell GI. Molecular biology of somatostatin receptors.
22. Yamada Y, Reisine T, Law SF, Ihara Y, Kubota A, Kagimoto S, Endocr Rev 1995;16:427-42.
Seino M, Seino Y, Bell GI, Seino S. Somatostatin receptors, an 40. Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and
expanding gene family: cloning and functional characterization its analogs in the diagnosis and treatment of tumours. Endocr Rev
of human SSTR3, a protein coupled to adenylate cyclase. Mol 1991;12:450-82.
Endocrinol 1992;6:2136-42. 41. Bousquet C, Puente E, Buscail L, Vaysse N, Susini C.
23. Ben-Shlomo A, Zhou C, Pichurin O, Chesnokova V, Liu NA, Antiproliferative effect of somatostatin and analogs. Chemotherapy
Culler MD, Melmed S. Constitutive somatostatin receptor 2001;47 Suppl 2:30-9.
activity determines tonic pituitary cell response. Mol Endocrinol 42. Butturini G, Bettini R, Missiaglia E, Mantovani W, Dalai I, Capelli
2009;23:337-48. P, Ferdeghini M, Pederzoli P, Scarpa A, Falconi M. Predictive
24. Cescato R, Loesch KA, Waser B, Mäcke HR, Rivier JE, Reubi JC, factors of efficacy of the somatostatin analogue octreotide as first
Schonbrunn A. Agonist-biased signalling at the sst2A receptor: line therapy for advanced pancreatic endocrine carcinoma. Endocr
the multi-somatostatin analogs KE108 and SOM230 activate Relat Cancer 2006;13:1213-21.
and antagonize distinct signalling pathways. Mol Endocrinol 43. Schally AV. Oncological applications of somatostatin analogues.
2010;24:240-9. Cancer Res 1988;48:6977-85.
25. Reubi JC, Eisenwiener KP, Rink H, Waser B, Mäcke HR. A 44. Weckbecker G, Raulf F, Stolz B, Bruns C. Somatostatin analogs for
new peptidic somatostatin agonist with high affinity to all five diagnosis and treatment of cancer. Pharmacol Ther 1993;60:245-64.
somatostatin receptors. Eur J Pharmacol 2002;456:45-9. 45. Pollak MN, Schally AV. Mechanisms of antineoplastic action of
26. Schonbrunn A. Selective agonism in somatostatin receptor somatostatin analogs. Proc Soc Exp Biol Med 1998;217:143-52.
signalling and regulation. Mol Cell Endocrinol 2008;286:35-9. 46. Froidevaux S, Eberle AN. Somatostatin analogs and radiopeptides
27. Ferone D, Arvigo M, Semino C, Jaquet P, Saveanu A, Taylor in cancer therapy. Biopolymers 2002;66:161-83.
JE, Moreau JP, Culler MD, Albertelli M, Minuto F, Barreca 47. Schally AV, Nagy A. Chemotherapy targeted to cancers
A. Somatostatin and dopamine receptor expression in lung through tumoural hormone receptors. Trends Endocrinol Metab
carcinoma cells and effects of chimeric somatostatin-dopamine 2004;15:300-10.
Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ August 31, 2016 ¦ 337